Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 09, 2022

Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Real-World Data

Current Oncology (Toronto, Ont.)

 

Additional Info

Current Oncology (Toronto, Ont.)
Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
Curr Oncol 2022 Feb 12;29(2)1047-1061, JW Law, D Mitra, HG Kaplan, T Alfred, AM Brufsky, B Emir, H McCracken, X Liu, RG Broome, C Zhang, C DiCristo, C Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading